Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer

This randomized clinical trial assesses progression-free survival among patients with RAS wild-type metastatic colorectal cancer receiving panitumumab plus standard-of-care trifluridine-tipiracil as third-line therapy.

• Publication year

  2023

• Venue

  JAMA Oncology

• Publication date

  2023-05-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2023.0655PMID 37200022PMCID 10196928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical management of metastatic colorectal cancer in the era of precision medicine

  2022cited by this paper
• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.

  2022cited by this paper
• Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

  2022cited by this paper
• CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients

  2022cited by this paper
• Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience

  2022cited by this paper
• Precision oncology in metastatic colorectal cancer — from biology to medicine

  2021cited by this paper
• Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.

  2021cited by this paper
• Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.

  2021cited by this paper
• Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer

  2021cited by this paper
• Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.

  2020cited by this paper
• Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

  2019cited by this paper
• Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

  2019cited by this paper
• Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

  2019cited by this paper
• Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience

  2019cited by this paper
• Adaptive mutability of colorectal cancers in response to targeted therapies

  2019cited by this paper
• APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).

  2018cited by this paper
• Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine

  2017cited by this paper
• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials †

  2017cited by this paper
• A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results.

  2017cited by this paper
• Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil

  2017cited by this paper
• Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

  2016cited by this paper
• Colorectal cancer: Overcoming resistance to anti-EGFR therapy — where do we stand?

  2016cited by this paper
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

  2016cited by this paper
• Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

  2015cited by this paper
• Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens

  2013cited by this paper
• GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]

  2013cited by this paper
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  2012cited by this paper
• Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

  2012cited by this paper
• Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.

  2012cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper

• Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS/BRAF wild-type chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.

  2026cites this paper
• Liquid biopsies in precision oncology for older adults with cancer.

  2026cites this paper
• Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling.

  2026cites this paper
• Clinical outcomes of treatments for patients with refractory metastatic colorectal cancer: a systematic literature review and network meta-analysis

  2026cites this paper
• What Is Next for Refractory Colorectal Cancer CRC? Looking Beyond SUNLIGHT, FRESCO2, RECURSE and CORRECT

  2025cites this paper
• Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.

  2025cites this paper
• Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology

  2025cites this paper
• Circulating tumor DNA in colorectal cancer: biology, methods and applications

  2025cites this paper
• Metastatic Colon Cancer Recurring After Cetuximab Plus Doublet Chemotherapy Harboring Acquired KRAS G12C Mutant that Responded to Sotorasib Plus Cetuximab.

  2025cites this paper
• Research trends and hotspots of circulating tumor DNA in colorectal cancer: a bibliometric study

  2025cites this paper
• Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial

  2025cites this paper
• Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions

  2025cites this paper
• Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study.

  2025cites this paper
• Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Liquid biopsy in gastrointestinal oncology: clinical applications and translational integration of ctDNA, CTCs, and sEVs

  2025cites this paper
• Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

  2025cites this paper
• Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

  2025cites this paper
• Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping

  2025cites this paper
• Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients.

  2025cites this paper
• The efficacy of targeted therapy and/or immunotherapy with or without chemotherapy in patients with Colorectal Cancer: A Network Meta-Analysis.

  2024cites this paper
• Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm

  2024cites this paper
• The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.

  2024cites this paper
• Error in Affiliations.

  2024cites this paper
• Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study

  2024cites this paper
• A panorama of colon cancer in the era of liquid biopsy

  2024cites this paper
• Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer

  2024cites this paper
• Targeting the EGFR signalling pathway in metastatic colorectal cancer.

  2024cites this paper
• Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group

  2024cites this paper
• The role of liquid biopsy as a catalyst for sustained progress in precision oncology – Perspective of the young committee of the international society of liquid biopsy

  2024cites this paper
• Cancer biotherapy: review and prospect

  2024cites this paper
• Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment

  2024influential citation
• Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC

  2024cites this paper
• Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial

  2024cites this paper
• Clinicopathological significance and prognostic analysis of p21 and EGFR in colorectal cancer: a retrospective analysis on 12 319 cases in China

  2024cites this paper
• Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study

  2024cites this paper
• Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial.

  2024cites this paper
• Application of ctDNA in Colorectal Cancer Detection

  2024cites this paper
• The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies

  2024cites this paper
• Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial

  2024cites this paper
• Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials

  2023cites this paper
• Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

  2023cites this paper
• Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer

  2023cites this paper
• Treatment of metastatic colorectal carcinoma - 3rd line and above

  2023cites this paper
• Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial

  2023influential citation